Tel.: +49 6221 868023
Fax: +49 6221 8680255

anti-human CD41, APC-conjugated, Clone TR8

CD41 (platelet glycoprotein IIb) is composed of two subunits (120 kDa a, alpha and 23 kDa b, ß) that interact with CD61 in the presence of calcium to form a functional adhesive protein receptor. Upon blood vessel damage, this receptor binds to a variety of proteins including von Willebrand factor, fibrinogen, fibronectin and vitronectin. CD41 is mainly expressed on megakaryocyte­-platelet lineage, but generally belongs to the antigens that are expressed during early stages of hematopoietic differentiation.

The monoclonal antibody ADG5033/L (clone TR8) is a murine monoclonal antibody, subclass IgG1. The antibody has been purified from by protein­-A affinity chromatography, Purity > 95% (by SDS­-PAGE). The antibody reacts with CD41 (GPIIb), a transmembrane glycoprotein (integrin family) composed of two chains GPIIbalpha (heavy chain; 120 kDa) and GPIIbß (light chain; 23 kDa). CD41 is mainly expressed on platelets and megakaryocytes.

The purified antibody is conjugated with cross-­linked Allophycocyanin (APC) under optimum conditions. The reagent is adjusted for direct use. No reconstitution is necessary.

Vial containing 500 µl (ADG5033) or 2 ml (ADG5033L) of purified antibody in PBS containing 1% BSA and 0.09% sodium azide (pH 7.2). The IgG concentration is 1 mg/ml. Spin the vial briefly before opening.

Storage and Stability
Store the antibody at 4°C. Avoid prolonged exposure to light. The reagent is stable until the expiry date stated on the vial label.

Flow Cytometry

Category: Research use only

Type: Antibody

Product Availability: Worldwide

Manufacturer: ImmBioMed GmbH & Co KG, Germany

For more information please click .pdf icon below.

anti-human CD41, APC-conjugated, Clone TR8

Cat.No. ADG5033
Artikelnr.: 938073

Einheit: 500 µl

Code: ADG5033

Hersteller: ImmBioMed GmbH & Co. KG


  1. Debili N, Robin C, Schiavon V, Letestu R, Pflumio F, Mitjavila­-Garcia MT, Coulombel L, Vainchenker W: Blood.
    2001 Apr 1;97(7):2023­-30.
  2. Mitjavila­-Garcia MT, Cailleret M, Godin I, Nogueira MM, Cohen­-Solal K, Schiavon V, Lecluse Y, Le Pesteur F, Lagrue AH, Vainchenker W: Development. 2002 Apr;129(8):2003­-13.
  3. Ferkowicz MJ, Starr M, Xie X, Li W, Johnson SA, Shelley WC, Morrison PR, Yoder MC: Development. 2003 Sep;130(18):4393­-403.
  4. Zhang J, Varas F, Stadtfeld M, Heck S, Faust N, Graf T: Exp Hematol. 2007 Mar;35(3):490­-499.

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzerklärung X